Dr Agarwals Health Care

Dr. Agarwal’s Health Care Limited - IPO

MAINBOARD

Dr Agarwals Health Care Stock Price

397.20 A2ZIPO
11.00 (2.85%)
16 May, 2025 12:14:54 PM | All Prices in ₹
Previous Close
386.20
Open
388.70
High
399.30
Low
382.75
Exchange
NSE
52 week High (13 Feb 2025)
464.00
52 week Low (07 May 2025)
330.00
Upper Price Band
463.40
Lower Price Band
309.00
Price Band
20.00%
394.05 A2ZIPO
7.85 (2.03%)
16 May, 2025 04:01:00 PM | All Prices in ₹
Previous Close
386.20
Open
387.20
High
399.50
Low
383.00
Exchange
BSE
52 week High
463.85
52 week Low
330.45
Upper Price Band
-
Lower Price Band
-
Price Band
-

Dr Agarwals Health Care IPO Details

Open Date
29 Jan 2025
Close Date
31 Jan 2025
Listing Date
04 Feb 2025
Issue Price
₹382 - ₹402
Face Value
₹1 per share
Lot Size
35
GMP
₹-4 (-1.0%)
Issue Type
IPO
Listing On
NSE, BSE
Type
Book Built Issue
Share holding pre issue
308417160
Share holding post issue
315879846
Total Issue Size
7,53,04,971 shares (aggregating up to ₹3027.26 Cr)
Fresh Issue
74,62,687 shares (aggregating up to ₹300.00 Cr)
Offer for Sale
6,78,42,284 shares (aggregating up to ₹2727.26 Cr)

Dr Agarwals Health Care IPO Subscription

Dr Agarwals Health Care IPO Application Wise Breakup (Approx)

Dr Agarwals Health Care IPO Dates

  • 29 Jan 2025
    Opening dateOPD
  • 31 Jan 2025
    Closing dateCOD
  • 01 Feb 2025
    Basis of AllotmentBOA
  • 03 Feb 2025
    Initiation of RefundsIOR
  • 03 Feb 2025
    Credit of SharesCOS
  • 04 Feb 2025
    Listing dateLID

Dr Agarwals Health Care IPO Lot Size

ApplicationLotsSharesAmount
Retain Minimum135₹14,070
Retain Maximum14490₹196,980
SHNI Minimum15525₹211,050
SHNI Maximum712485₹998,970
BHNI Minimum722520₹1,013,040

Dr Agarwals Health Care IPO Reservation

Promoter Holding

Pre Issue:37.73%
Post Issue:30.28%
Promoter Names:
Dr. Amar Agarwal, Dr. Athiya Agarwal, Dr Adil Agarwal, Dr. Anosh Agarwal, Dr Ashvin Agarwal, Dr. Ashar Agarwal, Dr. Amar Agarwal Family Trust, Dr Adil Agarwal Family Trust, Dr. Anosh Agarwal Family Trust, Dr Ashvin Agarwal Family Trust, Dr. Ashar Agarwal Family Trust, Dr Agarwal’s Eye Institute, Dr Agarwal's Eye Institute Private Limited

Dr Agarwals Health Care IPO Valuations

ROE:9.33%
ROCE:14.61%
RONW:6.21
PAT MARGIN:6.90
PRICE TO BOOK VALUE:7.96
EPS Pre IPO:3.08
EPS Post IPO:2.51
P/E Pre IPO:130.44
P/E Post IPO:160.48

Dr. Agarwal’s Health Care Limited Financial Information

Period Ended30 Sep 202431 Mar 202431 Mar 202331 Mar 2022
Assets3,393.412,752.821,825.171,026.13
Revenue837.941,376.451,031.49713.78
Profit After Tax39.5695.05103.2343.16
Net Worth1,502.671,337.68627.83212.34
Reserves and Surplus1,509.111,365.86652.63236.27
Total Borrowing373.68387.79356.18290.18
Amount in ₹ Crore

About Dr Agarwals Health Care IPO

Incorporated in 2010, Dr. Agarwal's Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.

As of September 30, 2024, there were 737 doctors providing care to patients across the company's facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries.

The Services provided by the company are:-

Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments;

Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).

Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium.

As of September 30, 2024, the company's Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities).

As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities.

Competitive Strength

  • Largest eye care services provider in India with a trusted brand
  • End-to-end, comprehensive eye care services offering
  • Scalable, asset-light, hub-and-spoke operating model
  • Proven clinical excellence is driven by a strong clinical board and a history of surgical innovations. 
  • Doctor-promoters leading a team of qualified medical professionals and supported by experienced management
  • Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability

Strength Of Dr Agarwals Health Care IPO

1. Largest eyecare services provider in India with a trusted brand.

2. End-to-end, comprehensive eyecare services offering.

3. Scalable, asset-light, hub-and-spoke operating model.

4. Proven clinical excellence driven by a strong clinical board and history of surgical innovations.

5. Doctor-promoters leading a team of qualified medical professionals and supported by an experienced management.

6. Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability.

Risk Of Dr Agarwals Health Care IPO

1. The company engage doctors through retainership arrangements and there is no assurance that its doctors will not prematurely terminate their arrangements with it. If the company is not able to attract and retain its doctors and other medical professionals, the company business, financial condition, results of operations and cash flows may be adversely affected.

2. The company business depends on the strength of the company brand equity and reputation. Failures to maintain and enhance its brand equity and reputation, including due to negative publicity, may adversely affect its business, reputation, financial condition, results of operations and prospects.

3. The company operates in a regulated industry, and its failures to comply with applicable safety, health, environmental, labor and other regulations, or to obtain or renew approvals, may adversely affect its business, reputation, financial condition, results of operations and cash flows.

4. A significant majority of its Facilities are located in the states of Tamil Nadu (in particular, Chennai), Maharashtra and Karnataka in India and any adverse developments in relation to these Facilities could adversely affect its business, financial condition, results of operations and cash flows.

5. The company is exposed to legal claims and regulatory actions arising from the provision of healthcare services and may be subject to liabilities arising from claims of malpractice and medical negligence which could adversely affect its business, financial condition, results of operations, cash flows, reputation and prospects.

6. Its international operations expose it to management, legal, tax, political and economic risks, and its failure to address such risks could adversely affect the company business, results of operations, financial condition and cash flows.

7. Its hub-and-spoke model may not be successful and the company may not be able to expand into new geographic regions, which could adversely affect its business, financial condition and results of operations.

8. The company has pursued and will likely continue to pursue strategic acquisitions for inorganic growth. Its inability to successfully identify, acquire and integrate suitable opportunities on commercially reasonable terms in the future could adversely affect its business, financial condition, cash flows and results of operations.

9. Its historical performance is not indicative of the company future growth or financial results and if its fail to manage the company growth or implement its growth strategies, the company business, financial condition and results of operations may be adversely affected.

10. The company is exposed to credit risks in respect of payments from third parties including under central and state government schemes, government corporations, insurance companies and third party administrators. If the company does not receive payments on a timely basis, its business, financial condition, results of operations, cash flows and prospects may be adversely affected.

Objectives Dr Agarwals Health Care IPO

  1. Repayment/prepayment, in part or full, of certain of the borrowings and
  2. General corporate purposes and unidentified inorganic acquisition.

Company Contact Details

Dr. Agarwal Health Care Limited
1 st Floor, Buhari Towers
No.4, Moores Road, Off Greams Road,
Near Asan Memorial School, Chennai 600 006
Phone: +91 44 4378 7777
Email: secretarial@dragarwal.com
Website: https://dragarwals.co.in/

Registrar Contact Details

Name: Kfin Technologies Limited
Phone: +91-40-67162222

Lead Mangers

  1. Kotak Mahindra Capital Company Limited

  2. Jefferies India Private Limited

  3. Morgan Stanley India Company Pvt Ltd

  4. Motilal Oswal Investment Advisors Limited

Comments